Shares of the direct-to-consumer telehealth company Hims & Hers have been halved over the past six months, trading near $27. Investors are now weighing whether the steep sell-off presents a buying opportunity or signals deeper troubles ahead.
Fulton Financial (FULT) shares have surged 16% in six months, outpacing the S&P 500. While the rally is impressive, a closer look at its fundamentals reveals potential headwinds in revenue growth, profitability, and book value expansion, prompting some analysts to suggest investors consider rotating capital elsewhere.
India's government has reaffirmed its stringent cryptocurrency taxation framework in the latest budget, leaving the controversial 30% levy and 1% transaction tax unchanged, dashing industry hopes for reform and cementing a policy that has already driven billions in trading volume offshore.
As Zurn Elkay Water Solutions prepares to report its quarterly results, investors are watching to see if the company can extend its impressive track record of exceeding revenue forecasts. We break down the key figures, peer performance, and market sentiment heading into the announcement.
A quiet crisis is eroding the foundation of U.S. economic decision-making. As key federal data agencies face budget cuts, political pressure, and operational challenges, the resulting information gap could leave policymakers and businesses 'flying blind,' increasing the risks of policy missteps, deeper recessions, and prolonged unemployment.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
While several stocks have posted impressive short-term gains, a closer look reveals a divergence between fleeting catalysts and fundamental strength. We analyze one surging name with a solid foundation and two others where caution may be warranted.
As IAC prepares to report quarterly results, investors are bracing for another potential revenue decline. We examine the key metrics, peer performance, and what the numbers could mean for the company's turnaround strategy.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
Initial drill results from the Senneville gold-silver-copper property in Quebec's prolific Val-d'Or camp have intersected significant near-surface mineralization, with intervals up to 57.8 meters, marking a promising start to the multi-phase exploration campaign.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
While trading near 52-week highs can signal strength, it can also precede a correction. We examine three stocks where current valuations may not justify the price tag, urging investors to look beyond the hype.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
While strong cash generation is a hallmark of a healthy business, it's not the whole story. We analyze three companies with solid cash flow, highlighting one that reinvests for growth and two where underlying risks may outweigh the financial metrics.
FirstSun Capital Bancorp's fourth-quarter results surpassed analyst forecasts, driven by robust net interest margins and loan growth. However, the post-earnings call revealed deeper questions from analysts about the sustainability of its performance and integration challenges.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
While geopolitical tensions have rattled regional markets, a closer look reveals resilient smaller companies in the GCC and Turkey offering unique value propositions. We analyze three firms with market caps under $900 million in the education, packaging, and industrial sectors.
As Thailand heads to the polls, Prime Minister Anutin Charnvirakul—a master political operator known for his ability to navigate crises—seeks to retain power. His tenure has been marked by strategic reversals, controversial policies, and the delicate balancing of conservative elites and public expectations.
